PUBLICATIONS

TALETRECTINIB

ESMO 2023 Poster Presentation

Efficacy and Safety of Taletrectinib in Patients with ROS1+ NSCLC: Interim Analysis of Global TRUST-II Study (pdf)

ELCC 2023 Mini Oral Presentation

Updated Efficacy and Safety of Taletrectinib in Patients with ROS1+ Non–Small Cell Lung Cancer (pdf)

Future Oncology

TRUST-II: a Global Phase II Study of Taletrectinib in ROS1-Positive Non-Small-Cell Lung Cancer and Other Solid Tumors

PMID: 36877099

ASCO 2022 Poster Presentation

TRUST: The Efficacy and Safety of Taletrectinib in TKI-Naïve or Crizotinib-Pretreated ROS1-Positive Non-Small Cell Lung Cancer (NSCLC) Patients (pdf)

ELCC 2022 Poster Presentation

A Global Phase 2 Study of Taletrectinib, a Next Generation of ROS1 TKI, in ROS1 Positive Lung Cancer and Other Solid Tumors (TRUST II) (pdf)

CSCO 2021 Oral Presentation

A Phase II Clinical Study to Investigate Taletrectinib (AB-106) in Treating Patients with ROS1 Fusion Positive Non-Small Cell Lung Cancer (TRUST Phase II study) (pdf)

ASCO 2021 Poster Presentation

Preliminary Results from TRUST: A Phase II Clinical Study to Investigate Taletrectinib in Treating Patients with ROS1 Fusion Positive Non-small Cell Lung Cancer (NSCLC) (pdf)

JTO Clinical and Research Reports

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

PMID: 34589973 PMCID: PMC8474193
DOI: 10.1016/j.jtocrr.2020.100108

Clinical Cancer Research

U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors

PMID: 32591465
DOI: 10.1158/1078-0432.CCR-20-1630

Nature Communications

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

PMID: 31399568 PMCID: PMC6688997
DOI: 10.1038/s41467-019-11496-z

Oncotarget

Safety and Pharmacokinetics of DS-6051b in Japanese Patients with Non-small Cell Lung Cancer Harboring ROS1 Fusions: a Phase I Study

PMID: 29805770 PMCID: PMC5955103
DOI: 10.18632/oncotarget.25263